Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRESERVE 1
2019-003826-25Phase 3Unknown
- Sponsor
- G1 Therapeutics, Inc.
- Start
- Oct 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in colorectal cancer (CRC) and metastatic colorectal adenocarcinoma (mCRC) comparing Trilaciclib arm with Placebo arm (2 arms). Primary endpoint: Duration of severe (Grade 4) neutropenia in Cycle 1. Status: unknown.
02
Drugs
trilaciclib
03
Conditions
colorectal cancer (CRC)metastatic colorectal adenocarcinoma (mCRC)
Beyond the preview
Go deeper on 2019-003826-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-003826-25.